Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2022 16:05 ET | Source: Larimar Therapeutics

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
October 20, 2022 08:00 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:...
October 19, 2022 16:05 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
September 16, 2022 13:00 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

BALA CYNWYD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments...
September 14, 2022 07:04 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces $70 Million Underwritten Offering

BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments...
September 14, 2022 07:01 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management hosting webcast and conference call today at 8:30 a.m. ET BALA...
August 11, 2022 16:05 ET | Source: Larimar Therapeutics

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose...
July 28, 2022 16:05 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
June 28, 2022 08:00 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts

BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
June 02, 2022 08:00 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Upcoming Scientific Conference Presentations

BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...